Early Beta-Blocker Utilization in Critically Ill Patients With Moderate-Severe Traumatic Brain Injury: A...

Area of Science:

• Critical Care Medicine
• Neurotrauma
• Pharmacology

Background:

• Limited evidence suggests potential benefits of beta-blockers for moderate-severe traumatic brain injury (TBI).
• Lack of large-scale studies on beta-blocker utilization and outcomes in clinical practice.

Purpose of the Study:

• Examine early beta-blocker utilization patterns in critically ill TBI patients.
• Assess the association between early beta-blocker use and clinical outcomes using a national claims database.

Main Methods:

• Retrospective cohort study of adults with moderate-severe TBI admitted to ICU (2016-2020).
• Exposure: beta-blocker receipt within the first 2 days of ICU stay.
• Outcomes: hospital mortality, length of stay, discharge disposition, vasopressor use; propensity weighting used for adjustment.

Main Results:

• No association between early beta-blocker use and hospital mortality (aOR=0.99, 95% CI [0.94, 1.04]).
• Beta-blocker use associated with longer hospital stays, lower discharge to home rates, and reduced vasopressor use (clinically small differences).
• No difference in mortality based on beta-blocker class (cardioselective vs. noncardioselective).

Conclusions:

• Significant variation exists in early beta-blocker use for TBI patients.
• Early beta-blocker exposure was not associated with hospital mortality in this cohort.
• Further research is required to determine optimal beta-blocker type, dose, and timing for TBI management.